Enprofylline

Enprofylline acts as a selective and competitive A2B receptor antagonist with the Ki of 7 μM. Enprofylline also acts as a phosphodiesterase inhibitor. Enprofylline can be used for the research of asthma, chronic obstructive pulmonary disease[1][2][3].

Product Specifications

CAS Number

[41078-02-8]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Adenosine Receptor; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/enprofylline.html

Purity

98.71

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C1NC(N(CCC)C2=C1NC=N2)=O

Molecular Formula

C8H10N4O2

Molecular Weight

194.19

Precautions

H302, H312, H332

References & Citations

[1]I Feoktistov, et al. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest. 1995 Oct;96 (4) :1979-86.|[2]M B Grant, et al. Proliferation, migration, and ERK activation in human retinal endothelial cells through A (2B) adenosine receptor stimulation. Invest Ophthalmol Vis Sci. 2001 Aug;42 (9) :2068-73.|[3]Jiang-Ning Yang, et al. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am J Physiol Heart Circ Physiol. 2009 Apr;296 (4) :H1141-9.